{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:26:26Z","timestamp":1786112786378,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003509","name":"\u00d6rebro University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003509","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Prim. Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Obesity is a growing global health burden, previously with few effective treatments. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were originally approved for diabetes but are increasingly prescribed for treatment of overweight and obesity. The increasing expenditure has led to ethical debates surrounding the utilization of these drugs. Few studies have investigated the attitudes to GLP-1 RAs among prescribing physicians. This study aimed to assess the attitudes to GLP-1 RAs for treatment of overweight and obesity among Swedish primary care physicians.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a cross-sectional survey with descriptive quantitative analysis and thematic analysis of free-text responses. A mix of multiple-choice questions and rating scales, including the Likert scale was employed. The study was conducted in October 2024 among physicians working in primary care in the Swedish regions of G\u00e4vleborg, Uppsala, V\u00e4sternorrland, V\u00e4stmanland and \u00d6rebro. The survey was distributed through the Drug and Therapeutics Committees (DTCs) in the regions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 190 responses yielded a response rate of 28%. Of these, 163 responses could be included in the final analysis. Almost all respondents (98%) agreed that GLP-1 RAs are effective drugs for treating obesity, and 91% believed they will be important for obesity treatment in the future. Main identified barriers for prescribing GLP-1 RAs were high patient co-payment (69%) and low drug availability due to supply shortages at the time of conducting this survey (86%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Physicians working in primary care in Sweden consider GLP-1 RAs effective for treating obesity and believe these drugs will play an important role in obesity treatment in the future. These findings should be interpreted in the light of the low response rate and possible self-selection bias.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12875-026-03488-y","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:52:46Z","timestamp":1785945166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Attitudes of Swedish primary care physicians toward GLP-1 receptor agonists for overweight and obesity: a cross-sectional survey"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1106-8276","authenticated-orcid":false,"given":"Isabelle","family":"Sundell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0531-2516","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Wettermark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2337-3371","authenticated-orcid":false,"given":"Anders","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6060-6229","authenticated-orcid":false,"given":"Mats","family":"Martinell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6710-875X","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Ericsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6188-9240","authenticated-orcid":false,"given":"Ulf","family":"Lindahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1489-5576","authenticated-orcid":false,"given":"Hussein N.","family":"Rubaiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8408-9588","authenticated-orcid":false,"given":"Maria Palmetun","family":"Ekb\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"issue":"10","key":"3488_CR1","doi-asserted-by":"publisher","first-page":"e24336","DOI":"10.2196\/24336","volume":"23","author":"MA Alvarez-Mon","year":"2021","unstructured":"Alvarez-Mon MA, Llavero-Valero M, Barco AA, Del Barco, Zaragoz\u00e1 C, Ortega MA, Lahera G, Quintero J, Alvarez-Mon M. Areas of Interest and Attitudes Toward Antiobesity Drugs: Thematic and Quantitative Analysis Using Twitter. J Med Internet Res. 2021;23(10):e24336.","journal-title":"J Med Internet Res"},{"issue":"1","key":"3488_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12875-022-01811-x","volume":"23","author":"D Carrasco","year":"2022","unstructured":"Carrasco D, Thulesius H, Jacobsson U, Memarian E. Primary care physicians\u2019 knowledge and attitudes about obesity, adherence to treatment guidelines and association with confidence to treat obesity: a Swedish survey study. BMC Prim Care. 2022;23(1):208.","journal-title":"BMC Prim Care"},{"key":"3488_CR3","unstructured":"Folkh\u00e4lsomyndigheten. Utveckling av BMI i Sverige 1980\u20132022. Stockholm: Folkh\u00e4lsomyndigheten; 2024. Available from: https:\/\/www.folkhalsomyndigheten.se\/publikationer-och-material\/publikationsarkiv\/u\/utveckling-av-bmi-i-sverige-1980-2022\/."},{"key":"3488_CR4","volume-title":"Prim\u00e4rv\u00e5rdens roll I sjukv\u00e5rdssystemet (The Role of Primary Care in the Healthcare System)","author":"T Forslund","year":"2019","unstructured":"Forslund T, Wettermark B. Prim\u00e4rv\u00e5rdens roll I sjukv\u00e5rdssystemet (The Role of Primary Care in the Healthcare System). Stockholm: Health and Medical Care Administration; 2019."},{"key":"3488_CR5","unstructured":"Elinder Sch\u00e4fer L, Fors S, Karnehed N, Tynelius P. Den oj\u00e4mlika obesitasv\u00e5rden [The unequal Obesity Care]. Stockholm: Centre for Epidemiology and Community Medicine, Region Stockholm; 2022. Rapport. 2022:3. Available from: https:\/\/www.ces.regionstockholm.se\/4ae458\/globalassets\/verksamheter\/forskning-och-utveckling\/centrum-for-epidemiologi-och-samhallsmedicin\/folkhalsoguiden\/rapporter-och-faktablad\/rapport-2022.3-den-ojamlika-obestitasvardentga.pdf."},{"key":"3488_CR6","unstructured":"Socialstyrelsen. Nationella riktlinjer f\u00f6r v\u00e5rd vid obesitas. Stockholm: Socialstyrelsen; 2024. Available from: https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/artikelkatalog\/nationella-riktlinjer\/2023-4-8460.pdf."},{"issue":"11","key":"3488_CR7","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1080\/14656566.2020.1748599","volume":"21","author":"KM Gadde","year":"2020","unstructured":"Gadde KM, Atkins KD. The limits and challenges of antiobesity pharmacotherapy. Expert Opin Pharmacother. 2020;21(11):1319\u201328.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"3488_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","volume":"21","author":"TD M\u00fcller","year":"2022","unstructured":"M\u00fcller TD, Bl\u00fcher M, Tsch\u00f6p MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discovery. 2022;21(3):201\u201323.","journal-title":"Nat Rev Drug Discovery"},{"key":"3488_CR9","doi-asserted-by":"publisher","unstructured":"Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. eClinicalMedicine. 2023;58:101882. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101882.","DOI":"10.1016\/j.eclinm.2023.101882"},{"issue":"13","key":"3488_CR10","doi-asserted-by":"publisher","first-page":"10449","DOI":"10.3390\/ijms241310449","volume":"24","author":"M-S Popoviciu","year":"2023","unstructured":"Popoviciu M-S, P\u0103duraru L, Yahya G, Metwally K, Cavalu S. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. Int J Mol Sci. 2023;24(13):10449.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3488_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.15605\/jafes.037.02.14","volume":"37","author":"HC Tan","year":"2022","unstructured":"Tan HC, Dampil OA, Marquez MM. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J ASEAN Federation Endocr Soc. 2022;37(2):65\u201372.","journal-title":"J ASEAN Federation Endocr Soc"},{"issue":"6","key":"3488_CR12","doi-asserted-by":"publisher","first-page":"e13435","DOI":"10.1111\/obr.13435","volume":"23","author":"J Iqbal","year":"2022","unstructured":"Iqbal J, Wu H, Hu N, Zhou Y, Li L, Xiao F, Wang T, Jiang H, Xu S, Huang B, Zhou H. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus\u2014a systematic review and meta-analysis of randomized control trials. Obes Rev. 2022;23(6):e13435.","journal-title":"Obes Rev"},{"issue":"11","key":"3488_CR13","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3390\/brainsci13111503","volume":"13","author":"D Arillotta","year":"2023","unstructured":"Arillotta D, Floresta G, Guirguis A, Corkery JM, Catalani V, Martinotti G, Sensi SL, Schifano F. GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach. Brain Sci. 2023;13(11):1503.","journal-title":"Brain Sci"},{"key":"3488_CR14","doi-asserted-by":"crossref","unstructured":"Vannabouathong C, Crotty C, Le K, Eurich D, Dyrda P. Current utilization patterns of glucagon-like peptide-1 receptor agonists: report [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022. Available from: https:\/\/canjhealthtechnol.ca\/index.php\/cjht\/article\/view\/HC0042.","DOI":"10.51731\/cjht.2022.434"},{"issue":"9","key":"3488_CR15","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00228-023-03539-8","volume":"79","author":"J Lin","year":"2023","unstructured":"Lin J, Pearson S-A, Greenfield JR, Park KH, Havard A, Brieger D, Day RO, Falster MO, de Oliveira Costa J. Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014\u20132022). Eur J Clin Pharmacol. 2023;79(9):1239\u201348.","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"3488_CR16","first-page":"101182","volume":"3","author":"A Javaid","year":"2024","unstructured":"Javaid A, Baviriseaty S, Javaid R, Zirikly A, Kukreja H, Kim CH, Blaha MJ, Blumenthal RS, Martin SS, Marvel FA. Trends in Glucagon-Like Peptide-1 Receptor Agonist Social Media Posts Using Artificial Intelligence. JACC: Adv. 2024;3(9):101182.","journal-title":"JACC: Adv"},{"issue":"1","key":"3488_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.japh.2023.10.002","volume":"64","author":"JH Watanabe","year":"2024","unstructured":"Watanabe JH, Kwon J, Nan B, Reikes A. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. J Am Pharmacists Association. 2024;64(1):133\u20138.","journal-title":"J Am Pharmacists Association"},{"issue":"5","key":"3488_CR18","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00228-025-03823-9","volume":"81","author":"A Fors","year":"2025","unstructured":"Fors A, Forslund T, Sundstr\u00f6m A, Wettermark B. Prescribing patterns of glucagon-like peptide-1 receptor agonists in the Swedish capital region-a register-based cross-sectional study. Eur J Clin Pharmacol. 2025;81(5):739\u201353. https:\/\/doi.org\/10.1007\/s00228-025-03823-9.","journal-title":"Eur J Clin Pharmacol"},{"key":"3488_CR19","unstructured":"Arthurson V, Ljung R. Fortsatt v\u00e4djan fr\u00e5n L\u00e4kemedelsverket: F\u00f6rskriv Ozempic endast till diabetespatienter [Internet]. Uppsala: L\u00e4kemedelsverket; 2024. Available from: https:\/\/www.lakemedelsverket.se\/sv\/nyheter\/fortsatt-vadjan-fran-lakemedelsverket-forskriv-ozempic-endast-till-diabetespatienter."},{"key":"3488_CR20","unstructured":"Arthurson V, Sundstr\u00f6m A, Ljung R. F\u00f6rskriv inte diabetesl\u00e4kemedel f\u00f6r viktnedg\u00e5ng [Internet]. Uppsala: L\u00e4kemedelsverket; 2023. Available from: https:\/\/www.lakemedelsverket.se\/sv\/nyheter\/forskriv-inte-diabeteslakemedel-for-viktnedgang."},{"issue":"5","key":"3488_CR21","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1185\/03007995.2016.1147025","volume":"32","author":"LS Matza","year":"2016","unstructured":"Matza LS, Curtis SE, Jordan JB, Adetunji O, Martin SA, Boye KS. Physician perceptions of GLP-1 receptor agonists in the UK. Curr Med Res Opin. 2016;32(5):857\u201364.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"3488_CR22","doi-asserted-by":"publisher","first-page":"e0260","DOI":"10.1097\/XCE.0000000000000260","volume":"11","author":"K Qureshy","year":"2022","unstructured":"Qureshy K, Ross Kirk A, Lyng Wolden M, Abbas Mohseni Zonoozi A, Liu A. A survey of physician experience and treatment satisfaction prescribing once-weekly semaglutide injections for patients with type 2 diabetes in Canada. Cardiovasc Endocrinol Metabolism. 2022;11(2):e0260.","journal-title":"Cardiovasc Endocrinol Metabolism"},{"issue":"4","key":"3488_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.18579\/jopcr\/v20i4.MS21083","volume":"20","author":"AY Aldhobaib","year":"2021","unstructured":"Aldhobaib AY, Rabbani SI, Mobark MA. Knowledge, Attitude and Practice about a Newer Class of Antidiabetic Drug (Glucagon-like peptide-1 receptor agonist) Among the Health Care Professionals of Qassim University, Saudi Arabia. J Pharm Res. 2021;20(4):58\u201366.","journal-title":"J Pharm Res"},{"issue":"4","key":"3488_CR24","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.pcd.2024.06.002","volume":"18","author":"J Lecomte","year":"2024","unstructured":"Lecomte J, de Beeck IO, Mamouris P, Mathieu C, Goderis G. Knowledge and prescribing behaviour of Flemish primary care physicians regarding novel glucose-lowering medications: Online cross-sectional survey. Prim Care Diabetes. 2024;18(4):441\u20137.","journal-title":"Prim Care Diabetes"},{"issue":"3","key":"3488_CR25","doi-asserted-by":"publisher","first-page":"e756","DOI":"10.1002\/osp4.756","volume":"10","author":"WT Garvey","year":"2024","unstructured":"Garvey WT, Mahle CD, Bell T, Kushner RF. Healthcare professionals\u2019 perceptions and management of obesity & knowledge of glucagon, GLP-1, GIP receptor agonists, and dual agonists. Obes Sci Pract. 2024;10(3):e756.","journal-title":"Obes Sci Pract"},{"key":"3488_CR26","doi-asserted-by":"crossref","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. \u2018Research electronic data capture (REDCap) \u2013 A metadata-driven methodology and workflow process for providing translational research informatics support\u2019, J Biomed Inform. 2009;42(2):377\u2009\u2013\u200981.","DOI":"10.1016\/j.jbi.2008.08.010"},{"issue":"1","key":"3488_CR27","first-page":"35","volume":"3","author":"A Barua","year":"2013","unstructured":"Barua A. Methods for decision-making in survey questionnaires based on likert scale. J Asian Sci Res. 2013;3(1):35\u20138.","journal-title":"J Asian Sci Res"},{"key":"3488_CR28","volume-title":"Fr\u00e5gor och svar \u2013 om fr\u00e5gekonstruktion i enk\u00e4t och intervjuunders\u00f6kningar (Questions and Answers \u2013 On Question Design in Survey and Interview Studies)","author":"A Persson","year":"2016","unstructured":"Persson A. Fr\u00e5gor och svar \u2013 om fr\u00e5gekonstruktion i enk\u00e4t och intervjuunders\u00f6kningar (Questions and Answers \u2013 On Question Design in Survey and Interview Studies). \u00d6rebro: SCB-tryck; 2016."},{"issue":"3","key":"3488_CR29","doi-asserted-by":"publisher","first-page":"152","DOI":"10.4103\/picr.picr_140_23","volume":"14","author":"P Ranganathan","year":"2023","unstructured":"Ranganathan P, Caduff C. Designing and validating a research questionnaire - Part 1. Perspect Clin Res. 2023;14(3):152.","journal-title":"Perspect Clin Res"},{"issue":"8","key":"3488_CR30","doi-asserted-by":"publisher","first-page":"e1001069","DOI":"10.1371\/journal.pmed.1001069","volume":"8","author":"C Bennett","year":"2011","unstructured":"Bennett C, Khangura S, Brehaut JC, Graham ID, Moher D, Potter BK, Grimshaw JM. Reporting Guidelines for Survey Research: An Analysis of Published Guidance and Reporting Practices. PLoS Med. 2011;8(8):e1001069.","journal-title":"PLoS Med"},{"issue":"5","key":"3488_CR31","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/poq\/nfr048","volume":"75","author":"NC Schaeffer","year":"2011","unstructured":"Schaeffer NC, Dykema J. Questions for Surveys: Current Trends and Future Directions. Pub Opin Q. 2011;75(5):909.","journal-title":"Pub Opin Q"},{"key":"3488_CR32","doi-asserted-by":"crossref","unstructured":"Robb M, Shellenbarger T. \u2018Mastering Survey Design and Questionnaire Development\u2019, The Journal of Continuing Education in Nursing. Edited by J.G. Jean Shinners.2020;51(6):248\u2013249.","DOI":"10.3928\/00220124-20200514-02"},{"issue":"9","key":"3488_CR33","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.4187\/respcare.11041","volume":"68","author":"LT Goodfellow","year":"2023","unstructured":"Goodfellow LT. An Overview of Survey Research. Respir Care. 2023;68(9):1309\u201313.","journal-title":"Respir Care"},{"issue":"2","key":"3488_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qualitative Res Psychol"},{"key":"3488_CR35","volume-title":"Pharmacologic Treatment of Overweight and Obesity in Adults\u2019, Endotext","author":"BG Tchang","year":"2000","unstructured":"Tchang BG, Aras M, Kumar RB, Aronne LJ, Feingold KR, Anawalt B, Blackman MR, et al. Pharmacologic Treatment of Overweight and Obesity in Adults\u2019, Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000."},{"issue":"6","key":"3488_CR36","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1177\/0253717620957496","volume":"42","author":"C Andrade","year":"2020","unstructured":"Andrade C. The Limitations of Online Surveys. Indian J Psychol Med. 2020;42(6):575\u20136.","journal-title":"Indian J Psychol Med"},{"issue":"3","key":"3488_CR37","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.2196\/jmir.6.3.e34","volume":"6","author":"G Eysenbach","year":"2004","unstructured":"Eysenbach G. Improving the Quality of Web Surveys: The Checklist for Reporting Results of Internet E-Surveys (CHERRIES). J Med Internet Res. 2004;6(3):e34.","journal-title":"J Med Internet Res"}],"container-title":["BMC Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-026-03488-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12875-026-03488-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-026-03488-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:52:49Z","timestamp":1785945169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12875-026-03488-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3488"],"URL":"https:\/\/doi.org\/10.1186\/s12875-026-03488-y","relation":{},"ISSN":["2731-4553"],"issn-type":[{"value":"2731-4553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"15 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants in this study provided their informed consent when answering the survey. The study was conducted in accordance with the principles of Good Clinical Practice and the Helsinki Declaration. According to Swedish Ethical Review Law on research involving humans [Lag (2003: 460) om etikpr\u00f6vning av forskning som avser m\u00e4nniskor], ethical approval of this study was not required since it targeted professionals on issues related to their work and not any sensitive patient data. A cover letter was sent along with the link to the survey explaining the study\u2019s purpose and highlighting the anonymity of the results. Participants were informed that their participation was voluntary, and consent was collected when respondents agreed to complete the questionnaire. Data were anonymous and treated confidentially so that no unauthorised persons could access them.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable since no individual data was obtained.","order":2,"name":"Ethics","label":"Consent of Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"289"}}